In Reply to Wang et al.

We appreciate the opportunity to reply to the letter 1 Wang T Tian G Chen X et al. In regard to Ying Li et al. Int J Radiat Oncol Biol Phys. 2021; 111: 583-584 Abstract Full Text Full Text PDF Scopus (2) Google Scholar regarding our manuscript. 2 Li Y Liu H Sun C et al. Comparison of clinical efficacy of neoadjuvant chemoradiotherapy between lower and higher radiation dose for carcinoma of the esophagus and gastroesophageal junction: A systematic review [e-pub ahead of print]. Int J Radiat Oncol Biol Phys. 2021; (, accessed July 7, 2021)https://doi.org/10.1016/j.ijrobp.2021.04.031 Abstract Full Text Full Text PDF Scopus (8) Google Scholar We strongly agree with the author's opinion concerning the reassessment of a preoperative radiation dose of more than 41.4 Gy for patients with operable esophageal cancer and carcinoma of the gastroesophageal junction (EC/GEJ) receiving neoadjuvant concurrent chemoradiation therapy (nCRT) because of the uncertain benefit of an additional 5 to 10 Gy escalation. Two important randomized trials (CROSS and NEOCRTEC5010 trial) using 41.4 or 40 Gy demonstrated promising data regarding numerically non-inferior survival compared with >41.4 Gy radiation. 3 Shapiro J van Lanschot J Hulshof M et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): Long-term results of a randomised controlled trial. Lancet Oncol. 2015; 16: 1090-1098 Abstract Full Text Full Text PDF PubMed Scopus (1257) Google Scholar ,4 Yang H Liu H Chen Y et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): A phase III multicenter, randomized, open-label clinical trial. J Clin Oncol. 2018; 36: 2796-2803 Crossref PubMed Scopus (250) Google Scholar